Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$8.87	$8.52	$3.96 ▼ $9.42	$246.71M	0.4	68,267 shs	31,949 shs
IVVD Invivyd	$0.97 -1.7%	$0.74	$0.35 ▼ $2.74	$118.94M	0.51	12.81 million shs	3.97 million shs
SOPH SOPHiA GENETICS	$3.46 +4.5%	$3.35	$2.58 ▼ $4.92	$223.69M	1	100,242 shs	15,015 shs
TLSA Tiziana Life Sciences	$1.81 -1.1%	$1.83	$0.63 ▼ $2.60	$213.83M	-0.57	416,227 shs	167,938 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	0.00%	+2.42%	+5.47%	+10.46%	+63.05%
IVVD Invivyd	-1.72%	+87.08%	+29.41%	+2.45%	+8.11%
SOPH SOPHiA GENETICS	+4.53%	-4.16%	+8.81%	+16.11%	-8.95%
TLSA Tiziana Life Sciences	-1.09%	-12.14%	-23.63%	+36.09%	+52.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Adherex Technologies	2.1064 of 5 stars	3.5	1.0	2.8	2.5	0.0
IVVD Invivyd	4.0623 of 5 stars	3.6	5.0	3.3	4.2	0.6
SOPH SOPHiA GENETICS	2.7246 of 5 stars	3.5	5.0	2.1	0.0	0.6
TLSA Tiziana Life Sciences	0.7074 of 5 stars	0.0	3.0	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.00	Buy	$13.33	50.32% Upside
IVVD Invivyd	3.25	Buy	$3.18	227.17% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	131.21% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IVVD, SOPH, FENC, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/25/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.00
8/21/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/15/2025	FENC Adherex Technologies	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
8/15/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $3.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	5.19	$0.03 per share	274.65	($0.27) per share	-32.85
IVVD Invivyd	$25.38M	4.61	N/A	N/A	$0.36 per share	2.70
SOPH SOPHiA GENETICS	$69.69M	3.36	N/A	N/A	$1.13 per share	3.06
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.42	N/A	N/A	N/A	-35.05%	N/A	-23.92%	11/6/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$0.92	N/A	8.85	N/A	-238.33%	-177.89%	-90.96%	11/13/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	11/4/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/13/2025 (Estimated)

Latest IVVD, SOPH, FENC, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FENC Adherex Technologies	-$0.06	-$0.11	-$0.05	-$0.11	$9.52 million	$9.76 million
8/14/2025	Q2 2025	IVVD Invivyd	-$0.04	-$0.12	-$0.08	-$0.12	$23.16 million	$11.79 million
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	4.85	4.59
IVVD Invivyd	N/A	1.33	1.33
SOPH SOPHiA GENETICS	0.62	3.39	3.21
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
IVVD Invivyd	70.36%
SOPH SOPHiA GENETICS	31.59%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
IVVD Invivyd	25.40%
SOPH SOPHiA GENETICS	4.88%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	10	27.81 million	24.54 million	Optionable
IVVD Invivyd	100	120.14 million	89.63 million	Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

IVVD, SOPH, FENC, and TLSA Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?

August 21, 2025 | marketbeat.com

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

August 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal Foralumab

August 14, 2025 | msn.com

Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab

August 14, 2025 | msn.com

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

August 14, 2025 | proactiveinvestors.com

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

August 14, 2025 | globenewswire.com

Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

August 11, 2025 | proactiveinvestors.com

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

August 11, 2025 | globenewswire.com

Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

July 21, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21, 2025 | globenewswire.com

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, SOPH, FENC, and TLSA Company Descriptions

Adherex Technologies NASDAQ:FENC

$8.87 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.88 +0.01 (+0.06%)

As of 08/29/2025 04:20 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Invivyd NASDAQ:IVVD

$0.97 -0.02 (-1.72%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.96 -0.01 (-0.82%)

As of 08/29/2025 07:59 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

SOPHiA GENETICS NASDAQ:SOPH

$3.46 +0.15 (+4.53%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.44 -0.02 (-0.58%)

As of 08/29/2025 04:10 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Tiziana Life Sciences NASDAQ:TLSA

$1.81 -0.02 (-1.09%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.85 +0.04 (+2.21%)

As of 08/29/2025 07:55 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time